medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Profiles of cognitive change in preclinical Alzheimerâ€™s disease using change-point analysis

Owen A Williamsa, Yang Ana, Nicole M Armstronga, Melissa Kitner-Trioloa, Luigi Ferruccib,
Susan M Resnicka
a

Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland
21224, USA
b
Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging,
Baltimore, MD, USA

______________________________________________________________________________
Abstract
Introduction: Change-point analyses are increasingly used to identify the temporal stages of accelerated cognitive decline in the preclinical stages of Alzheimerâ€™s Disease (AD). However, statistical comparisons of change-points between specific cognitive measures have not been reported.
Methods: 165 older adults (baseline age range: 61.1-91.2) from the Baltimore Longitudinal
Study of Aging developed AD during follow-up. Linear and non-linear mixed models were fit
for 11 cognitive measures to determine change-points in rates of decline before AD diagnosis.
Bootstrapping was used to compare the timing of change-points across cognitive measures.
Results: Change-points followed by accelerated decline ranged from 15.5 years (Card Rotations) to 1.9 years (Trail-Making A) before AD diagnosis. Accelerated decline in Card Rotations
occurred significantly earlier than all other measures, including learning and memory measures.
Discussion: Results suggest that visuospatial ability, as assessed by Card Rotations, may have
the greatest utility as an early predictive tool in identifying preclinical AD.
Key Words: Preclinical, Cognitive Decline, Change-point analysis, Visuospatial ability, Alzheimerâ€™s Disease

1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Introduction
Alzheimerâ€™s disease (AD) is a progressive
disease with a long preclinical phase in which
pathological markers are present for years
and even decades before clinical symptoms
[1]. Decline in episodic memory is a hallmark
of AD, but other cognitive domains are also
vulnerable to AD. [2] Understanding the temporal stages of the early acceleration of declines in various cognitive domains in preclinical AD is important for identifying individuals vulnerable towards accumulating AD
pathology and for characterizing AD progression prior to symptom onset.
The early preclinical phase of AD is characterized by beta amyloid (AÎ²) and phosphorylated tau accumulation with subsequent acceleration of brain atrophy in the absence of
clinical symptoms. [1, 3-5] With multiple
anti-amyloid clinical trials failing to show
that removal of AÎ² is associated with improved cognitive outcomes, [6] one argument
is that patients are not being targeted early
enough. [6, 7] The failures of clinical trials at
later disease stages have led to increasing focus on the earlier phases of disease, including
the asymptomatic preclinical stage, with the
hope that treatments at this stage may be
more effective. [8, 9] Thus, it is critical to define the earliest, and possibly subtle, changes
in cognitive performance in preclinical AD to
identify individuals who would have the
greatest potential to benefit from clinical interventions. To fully characterize cognitive
changes in preclinical AD, it is important to
examine a broad range of cognitive domains
and neuropsychological measures that may
be sensitive to the earliest changes.
One way of investigating the timing of cognitive decline prior to clinical AD diagnosis
is to use change-point analyses. Changepoint methods align participants by anchoring them at time of diagnosis to then examine

trajectories of variables of interest retrospectively for timepoints of change prior to clinical diagnosis. Change-points are identified
using piece-wise linear components separated by knots delineating between intervals
with differing rates of change. [10, 11] Previous studies using change-point analyses in
AD focused on verbal memory, [12, 13] reporting steeper declines in Immediate Recall,
measured by the picture version of the Free
and Cued Selective Reminding test, between
1 and 8.1 years before clinical diagnosis.
However, memory is not the only cognitive
domain subject to decline prior to AD onset
[2] and other domains have shown early
change-points. In a systematic review of
change-point studies in dementia and AD,
[14] the measure with the earliest changepoint, at 9.6 years before AD diagnosis, was
the Block design test assessing visuospatial
ability. [15] Measures associated with other
domains, i.e., language fluency and executive
function showed change-points detected at
6.8 years [16] and 2.9 years [13] prior to AD
diagnosis respectively.
While the systematic review by Karr et al.
[14] allows for a cursory comparisons of
change-points between measures associated
with various cognitive domains, the authors
highlight various methodological differences
between studies that make it difficult to draw
conclusions from such comparisons. For example, the maximum length of longitudinal
testing prior to AD diagnosis ranged from 930 years with frequency of visits varying between studies. Furthermore, the mean baseline ages in all studies ranged from 70-82
years, and analyses were adjusted by different sets of covariates. Therefore, the temporal
sequence of changes in different cognitive
domains in preclinical AD remains unclear.
To elucidate the temporal sequence of cognitive changes prior to clinical AD onset, we
investigated changes in rates of decline on
multiple cognitive measures, representing
2

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

specific cognitive domains, in individuals
who eventually developed AD. The aims of
this study were to identify how many changepoints best characterize the trajectories of
change in performance on several cognitive
measures and to find the earliest point in time
before AD diagnosis that accelerated decline
in performance could first be detected for
each measure.
Methods
Participants
Participants were from the Baltimore Longitudinal Study of Aging (BLSA), a longitudinal study started in 1958. [17] Participants
were community-dwelling volunteers who
were healthy at enrollment. During each visit,
they received comprehensive psychological
evaluations. For this study, we selected participants who were diagnosed with AD during follow-up and only used data from visits
when they had complete neuropsychological
testing data across the 11 measures investigated.
Clinical diagnosis of Alzheimerâ€™s disease
Clinical and neuropsychological data from
each participant were reviewed at a consensus case conference if their clinical dementia
rating score [18] was 0.5 or greater or if they
had more than three errors on the Blessed Information-Memory-Concentration Test, [19]
and participants were evaluated by case conference upon death or withdrawal. MCI status
was determined using the Petersen criteria.
[20] Diagnoses of dementia and AD were
based on criteria outlined in the Diagnostic
and Statistical Manual of Mental Disorders,
third edition, revised [21] and the National
Institute of Neurological and Communication
Disorders and Stroke â€“ Alzheimerâ€™s Disease
and Related Disorders, [22] respectively.

Neuropsychological measures
Participants were administered a comprehensive battery of cognitive measures assessing
verbal learning and memory, figural memory,

Table 1: Subject demographics
N Subjects
165
Total N assessments
998
Female (%)
83 (50.3)
White/nonwhite (%)
141 (85.5)/24
(14.5)
Baseline age
76.5 (7.4)
61.1-91.2
Education
16.7 (2.6)
8-21
Age at MCI onset
84.0 (6.1)
65-98
Age at AD diagnosis
86.5 (6.1)
65-102
Follow-up interval
8.3 (6.0)
0-24.1
Interval between MCI
2.5 (1.8)
onset and AD
0-10
Diagnosis

attention and processing speed, executive
function, language, and visuospatial ability.
Here, we provide a summary of each measure
used as outcomes in the present study.
The California Verbal Learning Test
(CVLT) [23] assesses episodic verbal learning and memory. There are 5 learning trials
of 16 shopping items, presented orally, with
four items from each of four semantic categories. The sum of the five trials provides a
measure of new learning and immediate free
recall. In addition, short- and long-delayed
free recall, short- and long-delayed cued recall, and recognition memory are assessed.
The two measures used were: total number of
items recalled across the five immediate free
recall trials (CVLT-IMM), and long-delay
free recall (CVLT-LD), with maximum
scores of 80, and 16, respectively.
3

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

The Benton Visual Retention Test (BVRT)
[24] measures visual constructional skill and
short-term figural memory. Participants
study 10 line-drawings, including one to
three geometric figures, for 10 seconds each,
and then immediately reproduce them from
memory using pencil and paper. The designs
become more difficult over the 10 trials. The
measure used was the total number of errors.
The Trail-Making Test Parts A (TMT-A) and
B (TMT-B) [25] assess attention, concentration, visuomotor scanning, perceptuomotor
speed, working memory, and set-shifting.
TMT-A involves drawing a line to connect
randomly arranged numbers from 1 to 25 in
sequential order. TMT-B involves connecting randomly arranged numbers and letters in
alternating sequence (e.g., 1-A-2-B . . .).
Time to completion for each test (in seconds)
was used in the present study.
Letter [26] and Category [27] Fluency are
measures of fluent language production and
executive function. Participants were given
60 seconds to generate as many words as possible beginning with specific letters and specific categories. The mean numbers of correct
words generated in 60 seconds, across the
three trials each for letter and category fluency, were the measures of interest.
The Boston Naming Test (BNT) [28] is a
measure of object recognition and semantic
retrieval. Participants identify and name a series of line drawings of objects, beginning
with common objects and ending with infrequent objects. The measure used was the
number of words out of 60 correctly named
without cues.
WAIS-R Similarities measures verbal concept formation and abstract reasoning. [29]
Participants are asked how 14 pairs of two
items are similar, starting with concrete items
and becoming increasingly abstract. The
measure of interest was the total score out of
a maximum of 28.

A modified version [30] of the Educational
Testing Service Card Rotations test was used
to measure visuospatial ability. Participants
were presented with a target figure and eight
alternative figures in the same row. Subjects
marked images that could be rotated in plane
to match the target, but not those that were
mirror image figures. The total number correct minus total number incorrect across the
two parts (14 targets per part) was the measure of interest, with a maximum score of 224.
The Mini Mental State Examination (MMSE)
[31] assesses mental status, including orientation to time and place, immediate and delayed recall, attention and calculation, and
language. Total score out of 30 was the measure of interest.
Statistical analyses
To find the number of change-points where
the rate of longitudinal decline changes significantly and the timing of these changepoints relative to AD diagnosis, a series of
linear and nonlinear mixed models with increasing complexity were fit with each of the
cognitive measures as the outcome and the
time (in years) to diagnosis of AD as the main
predictor. We started with a no change-point
model and then tested a one-change-point
model and finally a two change-points model.
The two-change-point model function is
given by
ğ‘Œğ‘Œğ‘–ğ‘–ğ‘–ğ‘– = ğ›½ğ›½0 + ğ‘ğ‘0ğ‘–ğ‘– + ğ›½ğ›½1 ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘–ğ‘–ğ‘–ğ‘– + ğ›½ğ›½2 ï¿½ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘–ğ‘–ğ‘–ğ‘– âˆ’
ğ‘ğ‘1 ï¿½+ + ğ›½ğ›½3 ï¿½ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘–ğ‘–ğ‘–ğ‘– âˆ’ ğ‘ğ‘2 ï¿½ + Æğ‘–ğ‘–ğ‘–ğ‘–
+

where (ğ‘¥ğ‘¥)+ = ğ‘¥ğ‘¥, ğ‘¥ğ‘¥ > 0 and (ğ‘¥ğ‘¥)+ = 0, ğ‘¥ğ‘¥ < 0.

ğ‘ğ‘1 is first change-point, ğ‘ğ‘2 is second changepoint. ğ‘ğ‘0ğ‘–ğ‘– is a random effect that follows a
normal distribution with mean 0 and standard
deviation of Ïƒ.
All models included baseline age, sex (male
vs. female), race (white vs. non-white), and
years of education as covariates. Model selections were based on the likelihood ratio
4

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Table 2: Fit statistics for models using no change-points, one change-point, or two
change points. Model fit was assessed using the likelihood ratio test, with bold text
indicating the current model provides significantly better fit compared to the one
prior.
No changepoints
6918.5/8

1 change2 changepoint
points
CVLT-IMM
-2 LL/DF
6745.4/10
6720.9/12
P value
<.0001
<.0001
CVLT-LD
-2 LL/DF
4629.7/8
4436.5/10
4428.9/12
P value
<.0001
0.022
BVRT
-2 LL/DF
5081.5/8
5013.0/10
5011.5/12
P value
<.0001
0.47
TMT-A
-2 LL/DF
8405.4/8
8302.8/10
8299.1/12
P value
<.0001
0.16
TMT-B
-2 LL/DF
8701.8/8
8626.8/10
8626.5/12
P value
<.0001
0.86
Categories
-2 LL/DF
4245.0/8
4073.8/10
4064.1/12
P value
<.0001
0.0078
Letters
-2 LL/DF
4582.4/8
4530.4/10
4523.9/12
P value
<.0001
0.039
BNT
-2 LL/DF
5152.7/8
4963.6/10
4949.9/12
P value
<.0001
0.0011
Similarities
-2 LL/DF
4221.8/8
4154.9/10
4147.3/12
P value
<.0001
0.022
Card Rotations
-2 LL/DF
7548.6/8
7468.6/10
7457.6/12
P value
<.0001
0.0041
MMSE
-2 LL/DF
3924.1/8
3726.4/10
3719.0/12
P value
<.0001
0.025
Abbreviations: BNT, Boston Naming Test; BVRT, Benton Visual Retention Test;
CVLT, California Verbal Learning Test; CVLT-IMM, CVLT immediate free recall;
CVLT-LD, CVLT long delayed free recall; MMSE, Mini Mental State Exam, TMTA, Trail-Making Test-A, TMT-B, Trail-Making Test-B; -2LL/DF, likelihood ratio.

test. The best model fit tells us how many
change-points, if any, there are for each cognitive measure.
The final model estimates were determined
by a bootstrapping method so that the parameter estimates, and standard errors can be accurately captured, and more importantly, the
timings of change-points from different

cognitive measures can be statistically compared. We used 500 randomly resampled
samples, with each sample having the same
sample size as the original one for the bootstrapping. The models were fit using PROC
NLMIXED in SAS 9.4 (Cary, NC).

5

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Table 3: Estimated change-points in years from AD diagnosis and slopes in test units change per year.
All estimates, standard errors, and p values are from bootstrapping.
Estimate (S.E.)
CVLT-IMM

Change-point 1

Change-point 2

-11.65 (0.80)

-2.80 (0.78)

Slope 1

Slope 2

Slope 3

0.23 (0.28)
-1.44 (0.25)
-3.74 (0.48)
P = 0.41
P < .0001
P < .0001
CVLT-LD
-7.58 (0.49)
-4.21 (0.33)
-0.080 (0.041) -0.48 (0.13)
-1.00 (0.091)
P = 0.051
P = 0.0002
P < .0001
BVRT *
-4.83 (0.81)
NA
0.36 (0.034)
0.99 (0.12)
NA
P < .0001
P < .0001
TMT-A*
-1.90 (0.68)
NA
0.59 (0.14)
9.01 (3.12)
NA
P < .0001
P = 0.0039
TMT-B*
-4.82 (0.73)
NA
1.68 (0.42)
11.86 (2.21)
NA
P < .0001
P < .0001
Categories
-9.89 (0.90)
-3.17 (0.41)
-0.13 (0.035) -0.34 (0.052) -0.97 (0.095)
P = 0.0002
P < .0001
P < .0001
Letters
-10.03 (1.39)
-2.25 (0.91)
-0.010 (0.047) -0.22 (0.058)
-0.69 (0.20)
P= 0.83
P = 0.00016
P = 0.00048
BNT
-6.04 (0.74)
-1.51 (0.57)
-0.10 (0.036)
-0.89 (0.17)
-2.06 (0.57)
P = 0.0043
P < .0001
P = 0.00033
Similarities
-10.65 (1.24)
-1.72 (0.53)
0.038 (0.054) -0.16 (0.043)
-0.84 (0.23)
P= 0.48
P = 0.00026
P = 0.00019
Card Rotation
-15.48 (1.72)
-4.33 (1.18)
1.66 (1.59)
-1.38 (0.35)
-4.74 (1.08)
P = 0.30
P < .0001
P < .0001
MMSE
-9.13 (0.92)
-1.77 (0.44)
-0.038 (0.024) -0.18 (0.033)
-1.03 (0.15)
P = 0.11
P < .0001
P < .0001
* These measures only had a single change-point. Abbreviations: : BNT, Boston Naming Test; BVRT,
Benton Visual Retention Test; CVLT, California Verbal Learning Test; CVLT-IMM, CVLT immediate free recall; CVLT-LD, CVLT long delayed free recall; MMSE, Mini Mental State Exam, TMT-A,
Trail-Making Test-A; TMT-B, Trail-Making Test-B; S.E., standard error.

Results
Sample characteristics are shown in Table 1.
The sample consisted of 165 participants
with an AD diagnosis with a total of 988 visits. Average baseline age was 76.5 years
(standard deviation, [SD]=7.4), the average
follow-up interval was 8.3 years (SD=6.0,
range=0-24.1), and average age at AD diagnosis was 86.5 years (SD=6.1). Eighty-three
(50.3%) participants were female, and 85.5%
of the sample were white. The average years
of education was 16.7 years (SD=2.6,
range=8-21).

Change-point model comparisons for each
cognitive measure
Table 2 contains the results of the model fit
statistics (likelihood ratio test) comparing the
fit of three models for each cognitive measure. Models with 1-change-point provided
better fit compared with no change-point
models for all cognitive measures. Models
with 2-change-points provided a better fit for
CVLT-IMM, CVLT-LD, Category Fluency,
Letter Fluency, BNT, Similarities, Card Rotations, and the MMSE. However, for the
BVRT, TMT-A, and TMT-B, the 2-changepoint model did not significantly improve the

6

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Figure 1: Line graphs showing the modelled population-level longitudinal trajectories from
change-point models (in red) superimposed over spaghetti plots of the raw data (gray) for each
cognitive measure. Vertical black lines indicate the change-points and the vertical red lines indicate timing of AD diagnosis. The X-axis represents years before AD diagnosis. Measurement
units: CVLT-IMM, total correct out of 80; CVLT-LD, total correct out of 16; BVRT, total number
of errors; TMT-A, seconds to complete; TMT-B, seconds to complete; Categories, mean number
correct words; Letters, mean number correct words; BNT, correct out of 60; Similarities, total our
of 28; Card Rotations, total out of 224; MMSE total out of 30.

7

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

model fit, indicating a 1-change-point model
was the best fitting model for these measures.
Temporal position of change-points and
subsequent rates of decline
Table 3 shows the results of parameter estimates from bootstrapping the best fitting
model for each cognitive measure, including
the estimated change-points, the rate of
change at each segment of the trajectory, and
corresponding standard errors (SE). Figure 1
shows the estimated trajectories superimposed over the raw data for each cognitive
measure.
Learning and memory
CVLT-IMM: The estimated first changepoint was 11.65 (SE=0.80) years before AD
diagnosis, when the trajectory transitioned
from non-significant increase in performance
over time (0.23 items per year, SE=0.28) to
significant moderate decline in performance
(-1.44 items per year, SE=0.25). The second
change-point was 2.80 (SE=0.78) years before AD diagnosis, when decline accelerated
again (-3.74 items per year, SE=0.48).
CVLT-LD: The estimated first change-point
was 7.58 (SE=0.49) years before AD diagnosis, when the trajectory transitioned from
trending-significant minor decrease in performance over time (-0.080 items per year,
SE=0.041) to significant moderate decline in
performance (-0.48 items per year, SE=0.13).
The second change-point was 4.21 (SE=0.34)
years before AD diagnosis, when decline accelerated again (-1.00 items per year,
SE=0.091).
BVRT: The estimated change-point was 4.83
(SE=0.81) years before AD diagnosis, when
the trajectory transitioned from significant
modest decline in performance over time
(0.36 errors per year, SE=0.034) to significant accelerated decline in performance (0.99
errors per year, SE=0.12).

Attention and executive function
TMT-A: The estimated change-point was
1.90 (SE=0.68) years before AD diagnosis,
when the trajectory transitioned from significant modest decline in performance over time
(0.59 seconds per year, SE=0.14) to significant accelerated decline in performance (9.01
seconds per year, SE=3.12).
TMT-B: The estimated change-point was
4.82 (SE=0.73) years before AD diagnosis,
when the trajectory transitioned from significant modest decline in performance over time
(1.68 seconds per year, SE=0.42) to significant accelerated decline in performance
(11.86 seconds per year, SE=2.21).
Verbal fluency
Category fluency: The estimated first
change-point was 9.89 (SE=0.90) years before AD diagnosis, when the trajectory transitioned from significant minor decrease in
performance over time (-0.13 words per year,
SE=0.035) to significant moderate decline in
performance (-0.34 words per year, SE =
0.052). The second change-point was 3.17
(SE=0.41) years before AD diagnosis, when
decline accelerated again (-0.97 words per
year, SE=0.095).
Letter fluency: The estimated first changepoint was 10.03 (SE=1.39) years before AD
diagnosis, when the trajectory transitioned
from non-significant minor decrease in performance over time (-0.010 words per year,
SE=0.047) to significant moderate decline in
performance (-0.22 words per year, SE =
0.058). The second change-point was 2.25
(SE=0.91) years before AD diagnosis, when
decline accelerated again (-0.69 words per
year, SE=0.20).
Object recognition and naming
BNT: The estimated first change-point was
6.04 (SE=0.74) years before AD diagnosis,
when the trajectory transitioned from significant minor decrease in performance over
time (-0.10 words per year, SE=0.036) to
8

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

significant moderate decline in performance
(-0.89 words per year, SE = 0.17). The second change-point was 1.51 (SE=0.57) years
before AD diagnosis, when decline accelerated again (-2.06 words per year, SE=0.57).
Abstract reasoning
Similarities: The estimated first change-point
was 10.65 (SE=1.24) years before AD diagnosis, when the trajectory transitioned from
non-significant increase in performance over
time (0.038 points per year, SE=0.054) to significant moderate decline in performance (0.16 points per year, SE=0.043). The second
change-point was 1.72 (SE=0.35) years before AD diagnosis, when decline accelerated
again (-0.84 points per year, SE=0.23).
Visuospatial ability
Card Rotations: The estimated first changepoint was 15.48 (SE=1.72) years before AD
diagnosis, when the trajectory transitioned
from non-significant increase in performance
over time (1.66 points per year, SE=1.59) to
significant moderate decline in performance
(-1.38 points per year, SE=0.35). The second
change-point was 4.33 (SE=1.18) years before AD diagnosis, when decline accelerated
again (-4.74 points per year, SE=1.08).
Global Cognitive Performance
MMSE: The estimated first change-point was
9.13 (SE=0.92) years before AD diagnosis,
when the trajectory transitioned from nonsignificant increase in performance over time
(-0.038 units per year, SE=0.024) to significant moderate decline in performance (-0.18
units per year, SE=0.033). The second
change-point was 1.77 (SE=0.47) years before AD diagnosis, when decline accelerated
again (-1.03 units per year, SE=0.15).
Comparing change-points across cognitive
measures
Figure 2 provides a schematic overview of
estimated change-points for each cognitive
measure. Table 4 shows the results from using bootstrapping to compare the first

change-points for each measure against all
other measures to identify the earliest changing measures. The measure with the earliest
change-point was Card Rotations, which was
significantly earlier than all other measures.
The next measure to show an early changepoint was CVLT-IMM, which was significantly earlier than CVLT-LD, BVRT, TMTA, TMT-B, BNT, and MMSE but not significantly earlier than measures of verbal fluency, or Similarities. The measure to show
the latest change-point in relation to AD diagnosis was TMT-A. Supplemental Table 1
shows the results from using bootstrapping to
compare the second change-points for each
measure. The second change-point for Card
Rotations was not significantly earlier than
the second change-points for CVLT
measures.
Discussion
In a sample of participants with consensus diagnoses of clinical AD, we used extensive
longitudinal cognitive data to examine the
temporal sequence of stages of decline in 11
cognitive measures. Change-points identifying steeper rates of cognitive decline ranged
from 15.5 years before AD diagnosis for the
Card Rotations test to 1.9 years before AD diagnosis for TMT-A. While episodic memory
assessed by CVLT measures was not the domain to show the earliest changes in rates of
decline, changes were still detected up to 11.7
years before AD diagnosis. Using changepoint analyses in this way can reveal the temporal ordering of domain-specific accelerated
decline in preclinical AD.
The change-point for Card Rotations (15.5
years before AD diagnosis) was significantly
earlier than change-points for all other cognitive measures, including CVLT measures of
episodic memory. This extends previous
findings from a systematic review [14] in
which it was casually observed that
9

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

Figure 2: Dot plot comparing the estimated change points relative to AD diagnosis across cognitive measures. Cognitive measures are presented in order of first change-points. Red dots represent first change-points and blue points represent second change-points. Extended lines show
standard errors. MCI indicates the average time of mild cognitive impairment symptom onset before AD diagnosis.

10

Table 4: The first change-point for each measure was compared between all measures using bootstrapping. P-values are presented to show which measures were significantly different from each other.

CVLT-IMM
CVLT-LD
BVRT
TMT-A
TMT-B
Categories
Letters
BNT
Similarities
Card Rotation
MMSE

CVLTIMM
1

CVLTLD
<.0001
1

BVRT

TMT-A

TMT-B

Categories

Letters

BNT

Similarities

<.0001
0.0029
1

<.0001
<.0001
0.0039
1

<.0001
0.0022
0.99
0.00063
1

0.13
0.031
<.0001
<.0001
<.0001
1

0.31
0.10
0.0018
<.0001
0.00057
0.93
1

<.0001
0.087
0.26
<.0001
0.27
0.0014
0.019
1

0.46
0.025
0.00012
<.0001
<.0001
0.64
0.73
0.0017
1

Card
Rotation
0.045
<.0001
<.0001
<.0001
<.0001
0.0041
0.010
<.0001
0.023
1

MMSE
0.031
0.13
0.00069
<.0001
0.00034
0.56
0.56
0.013
0.33
0.0015
1

Abbreviations: BNT, Boston Naming Test; BVRT, Benton Visual Retention Test; CVLT, California Verbal Learning Test;
CVLT-IMM, CVLT immediate free recall; CVLT-LD, CVLT long delayed free recall; MMSE, Mini Mental State Exam,
TMT-A, Trail-Making Test-A; TMT-B, Trail-Making Test-B.

11

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

visuospatial ability shows the earliest acceleration of cognitive decline prior to AD.
The underlying mechanisms that may lead to
early accelerated decline in visuospatial ability in preclinical AD may be understood from
the roles of the precuneus and other parietal
regions in visuospatial tasks that involve spatial manipulation (as is the case with the Card
Rotations Task in BLSA). [32] The precuneus is also part of a large network that includes medial temporal lobe and frontal lobe
regions that support spatial navigation. [33]
The precuneus is one of the earliest brain regions to show accumulation of AÎ² in preclinical AD [34, 35] and deficits in spatial navigation are one of the earliest impairments
leading to loss of independence. Taken together, the functional importance of the
precuneus in visuospatial processing and its
susceptibility to early AD pathology support
our finding that visuospatial ability would be
affected early in preclinical AD.
CVLT-IMM showed the second earliest
change-point at 11.7 years before diagnosis.
This change was significantly earlier than
CVLT-LD, which had a change-point at 7.6
years before AD diagnosis. The difference
between change-points for CVLT-IMM and
CVLT-LD is consistent with previous studies
that reported faster rates of verbal learning
compared to delayed free recall declines at
earlier stages of disease progression, [36, 37]
and confirms the importance of early learning
deficits in detecting individuals at risk of developing AD. [38] However, change-points
for CVLT-IMM were not significantly earlier
than those for measures of verbal fluency, the
Similarities Test, or the MMSE, suggesting
that some aspects of executive function, i.e.,
verbal concept formation and abstract reasoning, as well as aspects of mental status may
exhibit changes in the rates of decline as early
as some memory-based learning tasks. These
results contrast with earlier reports using
BLSA data indicating that memory is

affected earlier than executive function. [13]
One possible explanation for the different
pattern of results in the present analysis is the
larger number of participants with longer follow-up compared to previous reports.
Every cognitive measure examined showed
at least one change-point, with the majority
of measures exhibiting two change-points. In
measures with two change points, the first
change-point was always more than five
years before diagnosis while the second
change-point was less than five years before
diagnosis and was followed by even faster
rates of decline than the first change-point.
The second change-points appear to represent
the transition from preclinical AD to MCI.
The mean time between symptom onset of
MCI and AD diagnosis in our sample was 2.5
(SD=1.8) years. Accelerated cognitive declines in the years immediately prior to symptom onset and AD diagnosis are consistent
with other reports that MCI participants show
raster rates of decline compared to healthy
controls for a range of cognitive domains including memory, executive function, attention and verbal fluency. [39]
The temporal ordering of the first and second
change-points across cognitive measures
were similar. However, the second changepoint for Card Rotations was not significantly
earlier than the second change-points for
measures of memory or fluency, suggesting
that there is little difference in the sensitivity
of these measures as the time to diagnosis becomes shorter. As noted by Grober et al. [13]
the temporal unfolding of cognitive decline
identified by change-point studies implies
that the predictive utility of different
measures would be expected to vary by time
from AD diagnosis. As such, the temporal ordering of change-points in the present study
would suggest that measures of visuospatial
ability and memory may serve as predictive
tools for the development of AD as much as
15 years before diagnosis with other
12

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

measures becoming more relevant closer to
diagnosis. However, some measures of processing speed, i.e., TMT-A, may only have
predictive utility less than five years before
diagnosis, during a period when MCI may already be detectible. This interpretation is supported by previous reports of the predictive
power of different cognitive measures. [40]
A limitation of this study is that BLSA participants are a highly educated group, which
may limit generalizability. Additionally, the
focus of this study was on defining and comparing population-level change-points and as
such we did not examine individual differences in the timing of change-points which
requires longer follow-up at the individual
level. Future work is needed to assess individual differences in change-points. However, the strengths of this study are the comprehensive cognitive battery, frequent visit
schedule (subjects were tested annually or biannually in this sample) and consensus-based
determination of symptom onset and AD
diagnosis. In addition, the use of the bootstrapping analysis not only allows us to capture parameter estimates and standard errors
more accurately, but enables the statistical
comparison of change-points among different cognitive measures, greatly extending the
work of previous studies. [14]
In summary, we found that the cognitive
measure to show the earliest change in rates
of decline in preclinical AD was visuospatial
ability rather than episodic memory. Using
change-point analyses with bootstrapping
can reveal the temporal patterns of accelerated cognitive decline in preclinical AD and
may help guide the development of tools for
participant screening in clinical trials.
Acknowledgements
This research was supported entirely by the
Intramural Research Program of the National

Institutes of Health, National Institute on Aging. We thank the staff of the BLSA and LBN
cognitive testing group for their assistance
and the BLSA participants for their dedication to this study.
Declaration of interest
Declaration of interest: None.
References
[1] Sperling RA, Aisen PS, Beckett LA,
Bennett DA, Craft S, Fagan AM, et al.
Toward defining the preclinical stages of
Alzheimerâ€™s disease: Recommendations
from the National Institute on AgingAlzheimer's Association workgroups on
diagnostic guidelines for Alzheimer's
disease.
Alzheimer's
&
dementia.
2011;7:280-92.
[2] BÃ¤ckman L, Jones S, Berger A-K, Laukka
EJ, Small BJ. Cognitive impairment in
preclinical Alzheimer's disease: A metaanalysis. Neuropsychology. 2005;19:520-31.
[3] Armstrong NM, Huang C-W, Williams
OA, Bilgel M, An Y, Doshi J, et al. Sex
differences in the association between
amyloid and longitudinal brain volume
change in cognitively normal older adults.
NeuroImage: Clinical. 2019;22:101769.
[4] Jack Jr CR, Bennett DA, Blennow K,
Carrillo MC, Dunn B, Haeberlein SB, et al.
NIA-AA Research Framework: Toward a
biological definition of Alzheimer's disease.
Alzheimer's & Dementia. 2018;14:535-62.
[5] Villemagne VL, Burnham S, Bourgeat P,
Brown B, Ellis KA, Salvado O, et al.
Amyloid Î² deposition, neurodegeneration,
and cognitive decline in sporadic Alzheimer's
disease: a prospective cohort study. The
Lancet Neurology. 2013;12:357-67.
[6] van Dyck CH. Anti-amyloid-Î²
monoclonal antibodies for Alzheimerâ€™s
disease: pitfalls and promise. Biological
psychiatry. 2018;83:311-9.
13

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

[7] Sarazin M, DorothÃ©e G, de Souza LC,
Aucouturier
P.
Immunotherapy
in
Alzheimerâ€™s disease: do we have all the
pieces of the puzzle? Biological Psychiatry.
2013;74:329-32.
[8] Sevigny J, Chiao P, BussiÃ¨re T, Weinreb
PH, Williams L, Maier M, et al. The antibody
aducanumab reduces AÎ² plaques in
Alzheimerâ€™s disease. Nature. 2016;537:50.
[9] Sperling RA, Rentz DM, Johnson KA,
Karlawish J, Donohue M, Salmon DP, et al.
The A4 study: stopping AD before symptoms
begin? Science translational medicine.
2014;6:228fs13-fs13.
[10] Hall CB, Ying J, Kuo L, Lipton RB.
Bayesian and profile likelihood change point
methods for modeling cognitive function
over time. Computational Statistics & Data
Analysis. 2003;42:91-109.
[11] Hall CB, Ying J, Kuo L, Sliwinski M,
Buschke H, Katz M, et al. Estimation of
bivariate measurements having different
change points, with application to cognitive
ageing. Statistics in Medicine. 2001;20:3695714.
[12] Grober E, An Y, Lipton RB, Kawas C,
Resnick SMJJotINS. Timing of onset and
rate of decline in learning and retention in the
pre-dementia phase of Alzheimerâ€™s disease.
2019:1-7.
[13] Grober E, Hall CB, Lipton RB,
Zonderman AB, Resnick SM, Kawas C.
Memory impairment, executive dysfunction,
and intellectual decline in preclinical
Alzheimer's disease. Journal of the
International Neuropsychological Society.
2008;14:266-78.
[14] Karr JE, Graham RB, Hofer SM, MunizTerrera G. When does cognitive decline
begin? A systematic review of change point
studies on accelerated decline in cognitive
and neurological outcomes preceding mild
cognitive impairment, dementia, and death.
Psychology and aging. 2018;33:195.
[15] Thorvaldsson V, MacDonald SW,
Fratiglioni L, Winblad B, Kivipelto M,

Laukka EJ, et al. Onset and rate of cognitive
change before dementia diagnosis: findings
from two Swedish population-based
longitudinal studies. Journal of the
International Neuropsychological Society.
2011;17:154-62.
[16] Laukka EJ, MacDonald SWS,
Fratiglioni L, BÃ¤ckman L. Preclinical
Cognitive Trajectories Differ for Alzheimer's
Disease and Vascular Dementia. Journal of
the
International
Neuropsychological
Society. 2012;18:191-9.
[17] Shock NW. Normal human aging: The
Baltimore longitudinal study of aging. 1984.
[18] Morris JC. The Clinical Dementia
Rating (CDR): current version and scoring
rules. Neurology. 1993.
[19] Fuld PA. Psychological testing in the
differential diagnosis of the dementias.
Alzheimerâ€™s disease: senile dementia and
related disorders. 1978;7:185-93.
[20] Petersen RC. Mild cognitive impairment
as a diagnostic entity. Journal of internal
medicine. 2004;256:183-94.
[21] Association AP. Diagnostic and
Statistical Manual of Mental Health
Disorders
(DSM-III-R):
American
Psychiatric Association; 1987.
[22] McKhann G, Drachman D, Folstein M,
Katzman R, Price D, Stadlan EM. Clinical
diagnosis of Alzheimer's disease Report of
the NINCDSâ€ADRDA Work Group* under
the auspices of Department of Health and
Human Services Task Force on Alzheimer's
Disease. Neurology. 1984;34:939-.
[23] Delis DC, Kramer JH, Kaplan E,
Thompkins BAO. CVLT: California verbal
learning
test-adult
version:
manual:
Psychological Corporation; 1987.
[24] Benton AL. Visual retention test. New
York, NY: Psychological Corporation; 1974.
[25] Reitan RM. Trail Making Test: Manual
for administration and scoring: Reitan
Neuropsychology Laboratory; 1992.

14

medRxiv preprint doi: https://doi.org/10.1101/19009696; this version posted October 22, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available
for use under a CC0 license.

[26] Benton AL. Differential behavioral
effects
in
frontal
lobe
disease.
Neuropsychologia. 1968;6:53-60.
[27] Newcombe F. Missile wounds of the
brain: A study of psychological deficits.
1969.
[28] Kaplan E, Goodglass H, Weintraub S.
The Boston Naming Test (2nd ed.).
Philadelphia, PA: Lea & Febiger; 1983.
[29] Wechsler D. WAIS-R manual: Wechsler
adult
intelligence
scale-revised:
Psychological Corporation; 1981.
[30] Wilson JR, De Fries J, Mc Clearn G,
Vandenberg S, Johnson R, Rashad M.
Cognitive abilities: Use of family data as a
control to assess sex and age differences in
two ethnic groups. The International Journal
of Aging and Human Development.
1975;6:261-76.
[31] Folstein MF, Folstein SE, McHugh
PRJJopr. â€œMini-mental stateâ€: a practical
method for grading the cognitive state of
patients for the clinician. 1975;12:189-98.
[32] Cavanna AE, Trimble MRJB. The
precuneus: a review of its functional anatomy
and behavioural correlates. 2006;129:56483.
[33] Coughlan G, LaczÃ³ J, Hort J, Minihane
A-M,
Hornberger
MJNRN.
Spatial
navigation deficitsâ€”overlooked cognitive
marker for preclinical Alzheimer disease?
2018;14:496.
[34] Bilgel M, Prince JL, Wong DF, Resnick
SM, Jedynak BMJN. A multivariate
nonlinear mixed effects model for
longitudinal image analysis: Application to
amyloid imaging. 2016;134:658-70.
[35] Rodrigue K, Kennedy K, Devous M,
Rieck J, Hebrank A, Diaz-Arrastia R, et al. Î²Amyloid burden in healthy aging: regional
distribution and cognitive consequences.
2012;78:387-95.
[36] Bilgel M, An Y, Lang A, Prince J,
Ferrucci L, Jedynak B, et al. Trajectories of
Alzheimer
disease-related
cognitive

measures in a longitudinal sample.
2014;10:735-42. e4.
[37] Grober E, Kawas CJP, aging. Learning
and retention in preclinical and early
Alzheimer's disease. 1997;12:183.
[38] Chang Y-L, Bondi MW, FennemaNotestine C, McEvoy LK, Hagler Jr DJ,
Jacobson MW, et al. Brain substrates of
learning and retention in mild cognitive
impairment diagnosis and progression to
Alzheimer's disease. 2010;48:1237-47.
[39] Johnson JK, Gross AL, Pa J, McLaren
DG, Park LQ, Manly JJ, et al. Longitudinal
change in neuropsychological performance
using latent growth models: a study of mild
cognitive impairment. 2012;6:540-50.
[40] Saxton J, Lopez OL, Ratcliff G, Dulberg
C, Fried LP, Carlson MC, et al. Preclinical
Alzheimer disease: neuropsychological test
performance 1.5 to 8 years prior to onset.
2004;63:2341-7.

15

